Buchumschlag

Tolerability of BRAF and MEK inhibitors for metastasized melanoma after intra-class switch: a multicenter, retrospective study

Patients suffering from metastasized melanoma can be treated with three different combinations of tablets (“targeted therapy”), with similar efficacy but different side effect profiles. When one of the combinations is not tolerated well, their physicians may switch to a different combination; howeve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Salzmann, Martin (VerfasserIn) , Wald, Alexander (VerfasserIn) , Stege, Henner (VerfasserIn) , Loquai, Carmen (VerfasserIn) , Zimmer, Lisa (VerfasserIn) , Hayani, Kinan M. (VerfasserIn) , Heinzerling, Lucie (VerfasserIn) , Gutzmer, Ralf (VerfasserIn) , Enk, Alexander (VerfasserIn) , Hassel, Jessica C. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 23 February 2023
In: Cancers
Year: 2023, Jahrgang: 15, Heft: 5, Pages: 1-12
ISSN:2072-6694
DOI:10.3390/cancers15051426
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/cancers15051426
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2072-6694/15/5/1426
Volltext
Verfasserangaben:Martin Salzmann, Alexander Wald, Henner Stege, Carmen Loquai, Lisa Zimmer, Kinan M. Hayani, Lucie Heinzerling, Ralf Gutzmer, Alexander H. Enk and Jessica C. Hassel
Beschreibung
Zusammenfassung:Patients suffering from metastasized melanoma can be treated with three different combinations of tablets (“targeted therapy”), with similar efficacy but different side effect profiles. When one of the combinations is not tolerated well, their physicians may switch to a different combination; however, it has not been evaluated whether the second combination is actually tolerated better. ...
Beschreibung:Gesehen am 07.12.2023
Beschreibung:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers15051426

Ähnliche Einträge